← SynDRA
CABERGOLINE
SynDRA canonical compound SYN0023391 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | HTR2C |
|---|
| Mechanism of action | Dopamine receptor agonist |
|---|
| Indication | hyperprolactinemia |
|---|
| Disease area | endocrinology |
|---|
All known targets
- DRD2
- ADRA1A
- DRD4
- HTR2C
- HTR2B
- HTR2A
- HTR1D
- HTR1B
- HTR1A
- DRD5
- DRD3
- DRD1
Mechanisms of action (all sources)
- Dopamine receptor agonist
- DRD2 AGONIST
- Dopamine D2 receptor agonist
- HTR1A FULL AGONIST
- HTR1B FULL AGONIST
- HTR1D PARTIAL AGONIST
- HTR2A FULL AGONIST
- HTR2B FULL AGONIST
- HTR2C FULL AGONIST
- ADRA1A ANTAGONIST
- ADRA2A ANTAGONIST
- ADRA2B ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- KCNH2
- HRH2
- HRH1
- SLC6A3
- SLC6A2
- NR1I2
- NEIL1
- NR3C1
- NPY1R
- NEIL2
- ACHE
- MUTYH
- MLNR
- NTHL1
- MC3R
- MAOA
- MC4R
- OPRK1
- OPRD1
- OPRM1
- PDE3A
- PDE4A
- PDE4D
- PGR
- PTGS1
- PTGS2
- S1PR1
- SLC29A1
- SLC6A4
- SMUG1
- TBXA2R
- KDR
- HTR3A
- ADGRF1
- CHRM2
- ADORA1
- ADORA2A
- ADORA3
- AGTR1
- APLNR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT1A
- 5HT1B
- 5HT1D
- 5HT2A
- 5HT2B
- 5HT2C
- ACES
- ADA1A
- ADA2B
- ADA2C
- CP2D6
- CP3A4
- TADA2A
Drug classes
- Anti-Dyskinesia Agents
- Antiparkinson Agents
- Central Nervous System Agents
- Dopamine Agents
- Dopamine Agonists
- Neurotransmitter Agents
- Ergot Derivative
ATC classes
- G02C · OTHER GYNECOLOGICALS
- N04B · DOPAMINERGIC AGENTS
Cross-references
Synonyms
- DOSTINEX
- dostinex
- galastop
- cabaser
- cabaseril
- Cabergolina
- Velactis
- FCE-21336
- Cabaser
- Dostinex
- Cabaseril
- Cabergolinum
- Galastop
- Sogilen
- Cabergolina [Spanish]
- Cabergolinum [Latin]
- CG-101
- Cabaser (TN)
- Dostinex (TN)
- Cabergoline [USAN:BAN:INN]
- Cabergoline (JAN/USAN/INN)
- 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
- 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
- cabergoline (ema epar veterinary)
- cabergoline (ep monograph)
- FCE 21336
- LL60K9J05T
- cabergoline (usp-rs)
- cabergoline (usp monograph)
- CHEBI:3286
- DTXCID502719
- RefChem:57300
- G02CB03
- N04BC06
- MFCD00867887
- CAS-81409-90-7
- SR-05000001493
Reported adverse events
- Asthenia
- Constipation
- Depression
- Headache
- Nausea
- Acne
- Anxiety
- Breast pain
- Fatigue
- Hypotension
- Malaise
- Somnolence
Look up CABERGOLINE in the interactive SynDRA portal →